Gossypin

Gossypin is a bioflavonoid glycoside derived primarily from Hibiscus vitifolius that exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway and suppressing pro-inflammatory cytokine production. Preclinical research also highlights its anticancer and bone-protective properties through targeted molecular mechanisms including AURKA and RSK2 kinase inhibition.

Origin & History

Gossypin is a flavonoid glycoside primarily extracted from the Hibiscus vitifolius plant, traditionally used for its medicinal properties. The compound is isolated using standard phytochemical methods from the flowers or aerial parts of the plant.

Historical & Cultural Context

Hibiscus vitifolius, the source of gossypin, has been used in traditional medicine for treating diabetes and jaundice. These uses align with gossypin's observed antidiabetic and hepatoprotective activities in preclinical studies.

Health Benefits

• Inhibits NF-κB pathway, reducing inflammation and promoting apoptosis (preclinical evidence).
• Suppresses osteoclastogenesis, potentially benefiting bone health (in vitro studies).
• Inhibits gastric cancer cell growth via AURKA/RSK2 targeting (preclinical evidence).
• Exhibits antioxidant properties, which may protect cells from oxidative stress (in vitro studies).
• Shows potential antidiabetic and hepatoprotective effects (preclinical data).

How It Works

Gossypin suppresses the NF-κB signaling pathway by preventing IκB degradation, thereby reducing transcription of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. In cancer models, it directly inhibits Aurora Kinase A (AURKA) and ribosomal S6 kinase 2 (RSK2), disrupting cell cycle progression and promoting apoptosis in gastric cancer cells. Additionally, gossypin inhibits RANKL-induced osteoclastogenesis by downregulating NFATc1 and c-Fos expression, offering a mechanistic basis for its observed bone-protective effects.

Scientific Research

There are no human clinical trials or meta-analyses for gossypin. The evidence is limited to preclinical studies, including in vitro assays and animal models. No PMIDs are available for human studies.

Clinical Summary

The current body of evidence for gossypin is limited to in vitro cell studies and animal models, with no published human clinical trials as of 2024. In rodent models of arthritis, gossypin administration reduced paw edema and serum inflammatory markers by up to 60% compared to controls, mirroring indomethacin activity in some parameters. In vitro studies on human gastric cancer cell lines (SGC-7901) demonstrated dose-dependent growth inhibition with IC50 values in the low micromolar range, attributed to AURKA/RSK2 suppression. Until randomized controlled trials in humans are conducted, all purported benefits remain preliminary and should be interpreted with caution.

Nutritional Profile

Gossypin is a pure bioactive flavonoid compound (specifically a glycoside of gossypetin), not a whole food, so it lacks conventional macronutrients (proteins, fats, carbohydrates) or micronutrients in the dietary sense. Molecular formula: C21H20O13; molecular weight: 484.37 g/mol. It is a flavonol-8-glucoside (gossypetin-8-O-glucoside) found naturally in Hibiscus vitifolius, cotton plants (Gossypium species), and related Malvaceae family plants, typically at trace concentrations in plant tissues (estimated 0.1–2% dry weight in hibiscus flowers depending on extraction method). Key bioactive identity: belongs to the flavonol subclass of polyphenols, containing a hydroxylated flavone backbone with a glucose moiety at position 8, contributing to its water solubility relative to aglycone forms. Bioavailability is limited by intestinal absorption; as a glycoside, it requires hydrolysis by intestinal lactase-phlorizin hydrolase or colonic microbiota to release the aglycone gossypetin before significant absorption. Oral bioavailability is estimated to be low (<10% in preclinical models), consistent with other flavonol glycosides. No established Dietary Reference Intake (DRI) exists. Studied doses in preclinical settings range from 10–100 mg/kg body weight (animal models) and 10–50 µM concentrations (in vitro). Contains no fiber, protein, fat, or caloric value as an isolated compound. Antioxidant capacity measured via DPPH radical scavenging IC50 values reported in the range of 15–40 µg/mL in various in vitro assays.

Preparation & Dosage

No clinically studied dosage ranges are reported due to the absence of human trials. Preclinical in vitro studies use concentrations up to 25 mg/mL in DMSO, but no standardized dosing guidance is available for commercial products. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Curcumin, Resveratrol, Green Tea Extract, Vitamin C

Safety & Interactions

No formal human safety studies or established tolerable upper intake levels exist for gossypin, making definitive risk assessment difficult. Because gossypin inhibits NF-κB and shares mechanistic overlap with anti-inflammatory drugs, concurrent use with NSAIDs, corticosteroids, or immunosuppressants may produce additive effects and should be approached cautiously. Its potential to modulate cytochrome P450 enzyme activity, as observed with structurally related flavonoids, raises theoretical concerns about interactions with anticoagulants like warfarin or chemotherapeutic agents. Pregnant and breastfeeding individuals should avoid gossypin supplements due to a complete absence of safety data in these populations.